CTI BioPharma

CTI was founded on the belief that a coalition between unique scientific technology and its strong desire to “do right” by the patient could help us achieve our mission to acquire, develop and bring to market less toxic, more effective therapies to treat and cure cancer. We strive to do business better than other biopharmaceutical companies. Better means a more collaborative, well-trained team environment willing to institute novel approaches to scientific discovery and business opportunities. A willingness to push the limits to achieve challenging goals is the essential attribute that sets CTI employees apart.
Company Growth (employees)
Type
Public
HQ
Seattle, US
Founded
1992
Size (employees)
100 (est)
CTI BioPharma was founded in 1992 and is headquartered in Seattle, US

CTI BioPharma Office Locations

CTI BioPharma has an office in Seattle
Seattle, US (HQ)
600 3101 Western Ave

CTI BioPharma Data and Metrics

CTI BioPharma Financial Metrics

CTI BioPharma's revenue was reported to be $754 k in Q1, 2017
USD

Revenue (Q1, 2017)

754 k

Net income (Q1, 2017)

(19.8 m)

EBIT (Q1, 2017)

(19.3 m)

Market capitalization (21-Sep-2017)

104.6 m

Cash (31-Mar-2017)

33.3 m
CTI BioPharma's current market capitalization is $104.6 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

34.7 m60.1 m16.1 m57.4 m

Revenue growth, %

73%(73%)256%

Cost of goods sold

137 k895 k1.9 m1.4 m

Gross profit

34.5 m59.2 m14.2 m56 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

1.3 m39.5 m2.7 m1.1 m964 k36.5 m7.4 m4.4 m754 k

R&D expense

14 m16.5 m17.5 m19.3 m18.4 m20.8 m16.7 m17.7 m9.3 m

General and administrative expense

13.8 m12.6 m12.3 m12.6 m13.7 m11.3 m9.6 m15.2 m10.7 m

Operating expense total

27.8 m29.1 m29.8 m31.9 m32.1 m32.2 m26.3 m32.9 m19.9 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

71.6 m70.9 m128.2 m44 m

Accounts Receivable

235 k2 m282 k378 k

Inventories

3.6 m3.4 m3.7 m1.5 m

Current Assets

80.5 m80.5 m135 m55.8 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

33.2 m29.9 m44.4 m54.9 m46.4 m104.6 m76.7 m61.6 m33.3 m

Accounts Receivable

613 k1.2 m1.3 m880 k422 k666 k559 k620 k311 k

Inventories

5 m4.5 m3.6 m3.6 m2.6 m2.9 m2.6 m2.6 m1.5 m

Current Assets

42.3 m55.9 m53.5 m63.9 m53.3 m113.9 m88.9 m67.9 m36.8 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(43.6 m)(94.2 m)(120.8 m)(53 m)

Depreciation and Amortization

1.6 m1.1 m990 k831 k

Accounts Receivable

(227 k)(2 m)1.6 m(156 k)

Inventories

4.5 m46 k(402 k)567 k
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(27.4 m)(28.6 m)(32.6 m)(32.6 m)3.3 m(19.8 m)(29.2 m)(19.8 m)

Accounts Receivable

613 k1.2 m1.3 m880 k422 k666 k559 k620 k311 k

Inventories

5 m4.5 m3.6 m3.6 m

Accounts Payable

6.4 m6.3 m10.3 m11.2 m13.4 m17.7 m14 m13.7 m11.9 m
USDY, 2017

Revenue/Employee

7.5 k
Show all financial metrics

CTI BioPharma Operating Metrics

FY, 2016

Phase III Trials

2
Show all operating metrics

CTI BioPharma Market Value History

Traffic Overview of CTI BioPharma

CTI BioPharma Online and Social Media Presence

CTI BioPharma Company Life and Culture

You may also be interested in